Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price rose 7.3% on Monday . The company traded as high as $4.48 and last traded at $4.49. Approximately 8,441,095 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 13,691,540 shares. The stock had previously closed at $4.18.

Analysts Set New Price Targets

RXRX has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Finally, Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -3.21 and a beta of 0.99. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $6.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same period last year, the business earned ($0.39) earnings per share. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Private Trust Co. NA purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth about $27,000. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.